Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3727 - Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METAstatic Soft Tissue SARComa (STS) in a Real-Life Setting: an ancillary analysis of the METASARC Study

Date

11 Sep 2017

Session

Poster display session

Presenters

Sophie Cousin

Citation

Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387

Authors

S. Cousin1, M. Savina2, A. Le Cesne3, J. Blay4, I. Ray-Coquard5, O. Mir6, M. Toulmonde1, P. Terrier7, D. Ranchere-Vince8, P. Meeus9, E. Stoeckle10, C. Honore11, P. Sargos12, M.P. Sunyach13, C. Le Pechoux14, A. Giraud15, C. Bellera2, F. le loarer16, A. Italiano1

Author affiliations

  • 1 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 2 Department Of Epidemiology And Clinical Research, Institut Bergonié Régional Cancer Institute of Bordeaux, 33000 - Bordeaux/FR
  • 3 Department Of Medical Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 4 Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 5 Medical Oncology, Léon Bérard Center, 69008 - Lyon/FR
  • 6 Department Of Medical Oncology, Gustave Roussy Cancer Campus, 94800 - Villejuif/FR
  • 7 Department Of Pathology, Institut Gustave Roussy, Villejuif/FR
  • 8 Biopathology, Centre Leon Berard, Lyon/FR
  • 9 Chirurgie, Centre Léon Bérard, 69008 - Lyon/FR
  • 10 Surgery, Institute Bergonié, 33076 - Bordeaux/FR
  • 11 Surgery, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 12 Radiotherapy, Institute Bergonié, 33000 - bordeaux/FR
  • 13 Radiotherapy, Centre Leon Berard, 69008 - lyon/FR
  • 14 Radiation Oncology, Institut Gustave Roussy, Villejuif/FR
  • 15 Clinical And Epidemiological Research Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 16 Pathology, Institute Bergonié, 33000 - bordeaux/FR
More

Resources

Abstract 3727

Background

Treatment options for pts with advanced STS are limited. STS, like other proliferating malignancies, are dependent on the formation of new blood vessels to support their growth, invasion and metastasis. Growth Modulation Index (GMI) has been demonstrated as a relevant endpoint to assess clinical in patients with advanced STS. There are no data related to GMI in STS patients treated with anti-VEGFR targeted therapy.

Methods

Pts with metastatic STSs diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group who have received at least one TKI during their treatment were analysed. GMI, defined as the ratio of the Time To Progression (TTP2) under the TKI/TTP under the previous line of treatment (TTP1) was calculated.

Results

209 pts (102 male) were included in this study. Median age was 50 (11-83). 234 lines of TKI were administrated. The drugs used were: Pazopanib (77, 33%), Sorafenib (70, 30%), Sunitinib (45, 19%), Regorafenib (30, 13%), Others (12, 5%). The most frequent histology subtypes were: leiomyosarcoma (64, 30.6%), undifferentiated sarcoma (28, 13.4%), synovialosarcoma (20, 9.6%), desmoplastic round cell tumor (14, 6.7%) and angiosarcoma (11, 5.3%). Median of previous lines was 2 (0 – 4). Median TTP under TKI was 4.1 months (0 – 131.1). GMI was available for 201 pts. Median GMI was 0.76 (0.02 - 12.49). GMI was ≥ 1 in 87 (41.6%) pts and ≥ 1.3 in 65 (31.1%) pts. 17 pts received 2 consecutive lines of TKI. For these pts, median GMI (TTP under TKI2/TTP under TKI1) was 1 (0.12 – 8.77). Seven (41.2%) had a GMI ≥ 1.3.

Conclusions

Targeting VEGFR was associated with significant clinical benefit (GMI ≥ 1.3) in about one third of STS pts. Up to 41% of patients progressing on a TKI experienced clinical benefit with another TKI suggesting the lack of absolute cross-resistance between TKI.

Clinical trial identification

Legal entity responsible for the study

French Sarcoma Group

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.